Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flux Power Holdings Inc (FLUX) vs Eli Lilly And Co (LLY) Price & Performance

Flux Power Holdings IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Flux Power Holdings Inc vs Eli Lilly And Co — how do they compare? Flux Power Holdings Inc trades at $0.7 (market cap $15.37M), while Eli Lilly And Co trades at $1,174 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 67013.7× Flux Power Holdings Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.

FLUXLLY
Market Cap
$15.37M$1.03T
Sector
UtilitiesHealth
52-Week High
$6.66$1.24K
52-Week Low
$0.71$625.65
Enterprise Value
$21.53M$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flux Power Holdings Inc

FLUX trades at $0.701, down 2.18% today, with a bearish technical signal from moving averages. The company reported a net loss of $6.67M in 2025 with revenue of $66.43M, though the price-to-sales ratio remains low at 0.27. Recent news highlights the launch of SkyEMS 3.0 AI software and new executive hires aimed at growth. Analysts are unanimously bullish with 6 buy ratings, contrasting with negative profitability metrics like a -52.27% ROE.

The outlook hinges on execution of growth initiatives amid persistent losses. Opportunities include market expansion in clean energy and software, while risks involve cash flow volatility and competitive pressures. Investors should weigh analyst optimism against fundamental challenges in the evolving energy storage sector.

Eli Lilly And Co

LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.

Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Flux Power Holdings Inc

Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.

Read more on FLUX

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY